checkAd

     161  0 Kommentare Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum - Seite 3

    INVESTOR AND MEDIA CONTACT:

    Lesen Sie auch

    Jenene Thomas
    JTC Team, LLC
    833-475-8247
    NOVN@jtcir.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Novan Announces First Patient Enrolled and Dosed in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum - Seite 3 - Topline results targeted for Q2 2021, less than a year away - - SB206, if approved, has the potential to meet an important need for the treatment of molluscum, an area with no current FDA-approved treatment - MORRISVILLE, N.C., Sept. 03, 2020 …